What if one treatment could change how your body handles cholesterol for good? Researchers have now tested that idea in people for the first time and followed the results for a full year. The findings are early and come from a small group, but they raise a question that matters to anyone who has ever been told to get their numbers down. Here’s what the trial found, what still worries scientists, and what you can do while the research continues.
A One-Time Treatment for High LDL Cholesterol
LDL is the “bad” cholesterol. When you have too much of it in your blood, it sticks to the walls of your arteries and forms plaque. Over time, that raises your risk of a heart attack or stroke. Your genes, your diet, and your age all affect your LDL level. Most people bring it down with diet changes and statins, but not everyone responds to these. Some patients also need treatments they must take every day or every week.
CTX310 is an experimental treatment that aims to fix this with a single dose. It uses CRISPR, a gene-editing tool that can make a precise change in your DNA. Because the change is permanent, the effect is meant to last.
Here is how it works. Your liver makes a protein called ANGPTL3, which slows down how your body clears fats from your blood. Some people are born with a version of the gene that makes less of this protein. Their bodies clear blood fats faster, and their cholesterol stays lower. These people haven’t shown any health problems from it.
CTX310 copies that natural trait. It edits the gene in your liver cells so they make less ANGPTL3.
The treatment is given through an IV. It carries the gene-editing instructions inside tiny particles that travel through your blood to the liver.
What the First Human Trial Found
The trial was led by a team at the Cleveland Clinic Coordinating Center for Clinical Research, and the results were published in the New England Journal of Medicine. It was a phase 1a study, which means it was the first time CTX310 was tested in people.
Fifteen people took part. All of them had serious health problems linked to high cholesterol or high triglycerides, which are another type of fat in your blood. Their conditions had not improved with standard cholesterol drugs, so they had few other options. Each person received a single IV infusion of CTX310.
The biggest changes showed up in the four people who got the highest dose. On average:
- ANGPTL3 levels dropped by 78.6%.
- LDL cholesterol dropped by 52.5%.
- Triglycerides dropped by 47.8%.
The researchers followed the group for a year, and the effects lasted. In 14 of the 15 participants, cholesterol and triglyceride levels stayed low at the 12-month check. This matters because the whole idea behind CTX310 is a lasting result from one treatment, not a short-term drop.
Keep in mind that this was a small group, and it was a first test. These results don’t prove the treatment works for everyone with high cholesterol. They do show that the approach can lower cholesterol and triglycerides in people who needed help, and that’s enough for the researchers to keep developing it.
Safety and the Risks of Gene Editing
Safety was a main focus of this trial, and the researchers reported few adverse events overall.
One participant died 179 days after receiving CTX310. The researchers reviewed the case and concluded the death was unrelated to the treatment. In the other 14 participants, no new serious adverse events were reported over the full year of follow-up.
That is encouraging, but it’s a limited picture. Fifteen people is a small group, and one year is a short time to judge a treatment meant to last a lifetime. Rare side effects usually don’t show up until a treatment is tested in many more people.
Gene editing also carries risks in general. CTX310 makes a permanent change in your DNA, so the question isn’t only how you feel in the first weeks after the infusion. Researchers need to know how the change affects people five, ten, or twenty years later. The team did choose its target carefully, since it copies a variation that some people are born with and that hasn’t been linked to health problems. Still, a naturally occurring variant and an edit made in adulthood are not guaranteed to behave the same way, which is why longer studies matter.
The participants were also a specific group. They had lipid disorders that didn’t respond to standard drugs, so the risks and benefits may look different for someone whose cholesterol is controlled with a statin.
What Comes Next
CTX310 is still an experimental treatment, and you can’t get it outside a clinical trial. The next step is already underway. A phase 1b trial is now testing whether the results from the first study hold up. Instead of comparing several doses, this trial uses one fixed dose, matching the highest dose from phase 1a, since that one produced the largest drops in cholesterol and triglycerides.
The new trial also looks at specific groups of patients. Researchers are testing CTX310 in separate cohorts, each with a particular lipid disorder. This will show whether the treatment works better for some conditions than others.
Several questions remain open. Researchers need to test CTX310 in many more people and follow them for much longer than one year. They need to confirm that the cholesterol drop lasts, and that no new safety concerns appear over time. Only then can they say whether the treatment is viable.
If it does hold up, the benefit would be practical. A single treatment could replace medications that patients must take daily or weekly. Many people find it hard to stick with a drug schedule for decades, and a one-time option would remove that problem.
For now, nothing changes for your own care. If you take a statin or another cholesterol medication, keep taking it as prescribed, and talk with your doctor before making any changes. If your cholesterol stays high despite treatment, ask your doctor whether a clinical trial might be an option for you.
My Personal RX on Keeping Your Cholesterol in Check
A one-time gene-editing treatment for cholesterol is still in early testing. The daily habits that affect your cholesterol are in your hands right now, and they are the same ones I recommend to my patients. Here are my personal tips.
- Know Your Numbers:Β Ask your doctor for a lipid panel, and check your LDL, HDL, and triglycerides on the schedule your doctor recommends.
- Take Your Medication as Prescribed:Β If you take a statin, keep taking it. Don’t stop or change the dose without talking to your doctor.
- Eat More Soluble Fiber:Β Oats, beans, lentils, and apples help lower LDL. Add one of them to your day and build from there.
- Swap Your Fats:Β Replace butter and fried foods with olive oil, nuts, and fish.
- Move Most Days:Β A 30-minute brisk walk helps lower triglycerides and raise HDL.
- Lose Extra Weight Gradually:Β Even a modest loss can improve your LDL and triglycerides. TheΒ Weight Loss BundleΒ pairs well with a whole-food diet to curb cravings and keep your energy steady.
- Eat Fish Twice a Week:Β Salmon, sardines, and trout supply omega-3 fats. If you rarely eat fish,Β Omega-3 Fish Oil supports heart health. Check with your doctor first if you take blood thinners.
- Quit Smoking:Β Smoking lowers HDL and damages your artery walls. Ask your doctor for help quitting.
- Limit Alcohol:Β Heavy drinking raises triglycerides. Keep it moderate, or skip it.
- Follow a Plan:Β MyΒ Protocol For Optimizing Your Health & WellbeingΒ puts nutrition, movement, and lifestyle changes into one step-by-step guide you can follow.
Sources:
- Nield, D. (2026, September 4).Β Experimental One-Dose Treatment Cuts βBadβ Cholesterol by 52% in First Human Trial. ScienceAlert. https://www.sciencealert.com/experimental-one-dose-treatment-cuts-bad-cholesterol-by-52-in-first-human-trial
- Laffin, L. J., Nicholls, S. J., Scott, R. S., Clifton, P. M., Koops, R., Sarraju, A., Singh, S., Wang, Q., Wolski, K., Xu, H., Nielsen, J., Patel, N., Duran, J. M., & Nissen, S. E. (2026). Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310.Β New England Journal of Medicine. https://doi.org/10.1056/nejmc2609825
